ST6GALNAC5 (ST6 N-acetylneuraminic Acid Alpha-2,6-Sialyltransferase 5) <table class="infobox infobox-protein">
Overview bfe67bb53c3c532ef4237fa3323691ae27404769
Structure ...
ST6GALNAC5 (ST6 N-acetylneuraminic Acid Alpha-2,6-Sialyltransferase 5) <table class="infobox infobox-protein">
Overview bfe67bb53c3c532ef4237fa3323691ae27404769
Structure ST6GALNAC5 is a type II transmembrane protein with the following structural organization: [@huang2022]
Domain organization:
N-terminal transmembrane domain : Anchors the enzyme in the Golgi membraneStem region : Short region connecting TM to catalytic domainCatalytic domain : Contains the sialyltransferase active site with a DXH motif and a second histidine for donor substrate bindingST6GALNAC5 differs from the related ST6GAL1 (widely expressed in liver and many tissues) in its cell type specificity, substrate preference, and brain-enriched expression pattern. [@boscher2021]
bfe67bb53c3c532ef4237fa3323691ae27404769
Under physiological conditions, ST6GALNAC5 participates in glycosylation remodeling that supports normal astrocyte function: [@voss2023]
Astrocyte-Neuron Communication Astrocytes use sialylated glycoproteins to communicate with neurons:
Surface signaling : Sialylated proteins on astrocyte surface interact with siglec receptors on neuronsSynaptic support : Normal astrocyte sialylation contributes to synaptic maintenance and functionIon regulation : Astrocyte sialylated proteins participate in potassium siphoningBrain Development During development, ST6GALNAC5 is involved in:
Neuronal migration (sialylated proteins on glial cells guide migrating neurons)
Synaptogenesis (astrocyte-derived sialylated factors promote synapse formation)
Axon guidance (glycosylation patterns create molecular cues)
Glycosylation Homeostasis The enzyme maintains the balance of sialylated glycoconjugates in the brain:
Modifies surface proteins of astrocytes with alpha-2,6-linked sialic acid
Sialylated proteins can regulate complement activation and immune recognition
Contributes to the glycocalyx of astrocyte end-feet at the neurovascular unit
Role in Alzheimer's Disease
Astrocyte Reactivity In AD, astrocytes become reactive (astrogliosis) and ST6GALNAC5 expression is significantly upregulated: [@stgalnac2024]
Aβ exposure response : Exposure to amyloid-beta oligomers induces ST6GALNAC5 transcriptionSynaptic toxicity mechanism : Elevated ST6GALNAC5 in astrocytes drives synaptic loss through a non-cell-autonomous mechanismSialic acid accumulation : Increased ST6GALNAC5 leads to hyper-sialylation of astrocyte surface proteins, altering their signaling propertiesA 2024 Nature Neuroscience study demonstrated: [@stgalnac2024]
ST6GALNAC5 is specifically upregulated in reactive astrocytes in AD brains Astrocyte-specific knockdown of ST6GALNAC5 improves spatial memory in 5xFAD AD mouse modelsSynaptic integrity is preserved in the hippocampus when ST6GALNAC5 is reducedNeuroinflammation is reduced through modulation of astrocyte activation stateAstrocyte-to-neuron signaling is normalized when ST6GALNAC5 is silenced
Mechanism The current model proposes: [@li2023]
Mermaid diagram (expand to render)
Downstream Pathways
Siglec receptor dysregulation : Sialylated astrocyte proteins engage inhibitory Siglec receptors on neurons, suppressing survival signalingCytokine dysregulation : ST6GALNAC5 knockdown reduces IL-1β, TNF-α, and IL-6 release from astrocytesSynaptic protein loss : Presynaptic markers (synaptophysin, vGLUT1) are preserved when ST6GALNAC5 is reducedConnection to Other AD Pathologies
Amyloid-Beta
ST6GALNAC5 expression is induced by Aβ oligomers through NF-κB pathway activation
Sialylated proteins may facilitate Aβ aggregation or its effects on glia
Reduction of ST6GALNAC5 protects against Aβ-induced synaptic loss
Tau Pathology
Indirect effects through neuroinflammation
Synaptic protection appears partially independent of tau pathology
May affect tau spread by modulating astrocyte-mediated phagocytosis
Therapeutic Potential ST6GALNAC5 is an attractive therapeutic target because: [@kremer2021]
Astrocyte-specific expression provides tissue/cell type selectivityKnockdown shows clear benefit in animal models of ADAstrocyte-targeting is feasible with AAV vectors (e.g., GFAP promoter-driven shRNA)
Glycosylation in Neurodegeneration ST6GALNAC5 is part of a broader picture linking glycosylation to neurodegeneration: [@boscher2021]
Altered glycosylation is observed across neurodegenerative diseasesSiglec receptors (sialic acid-binding immunoglobulin-type lectins) are key mediators of glia-neuron cross-talkSialic acid metabolism is increasingly recognized as a modulator of neuroinflammationOther sialyltransferases implicated in brain function include:
ST3GAL1/ST3GAL2 : Alpha-2,3-sialylation; roles in synaptic gangliosidesST6GAL1 : Systemic sialylation; linked to inflammationST8SIA1/ST8SIA2 : Polysialic acid synthesis; neural plasticitySee Also
[Astrocytes in Alzheimer's Disease](/cell-types/astrocytes-alzheimers)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-hypothesis)
[Amyloid-Beta Oligomers](/proteins/amyloid-beta)
[Glycosylation in Neurodegeneration](/mechanisms/glycosylation-neurodegeneration)
[Siglec Receptors](/mechanisms/siglec-receptors)
External Links bfe67bb53c3c532ef4237fa3323691ae27404769
Show full description